Opdivo

(Nivolumab)

ApprovedMonoclonal antibody

Nivolumab is used to treat certain types of cancer, including melanoma, lung cancer, and kidney cancer, by helping the body's immune system recognize and attack cancer cells.[2] Opdivo is currently approved and in use across 234 indications[4].[1]

Opdivo is one of 2030 monoclonal antibody programs targeting Classic Hodgkin Lymphoma. It is currently in Approved.

234

Indications

1,505

Total Trials

Active Trials

2,029

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Classic Hodgkin LymphomaActive, not recruiting

Head and Neck Squamous Cell CarcinomaRecruiting

Renal Cell CarcinomaCompleted

GliomaActive, not recruiting

Esophageal AdenocarcinomaCompleted

Endometrial CancerActive, not recruiting

Mucosal MelanomaWithdrawn

MelanomaCompleted

NeuroblastomaActive, not recruiting

Urothelial CarcinomaCompleted

Classic Hodgkin LymphomaPhase 2

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 2

Recruiting

Renal Cell CarcinomaApproved

Completed

GliomaPhase 2

Active, not recruiting

Esophageal AdenocarcinomaPhase 2

Completed

Endometrial CancerPhase 2

Active, not recruiting

Mucosal MelanomaPhase 2

Withdrawn

MelanomaPhase 3

Completed

NeuroblastomaPhase 1

Active, not recruiting

Urothelial CarcinomaPhase 3

Completed

Showing 10 of 234 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Approved

22 2

Voltaren

Novartis

Preclinical

1 3

Spravato

WWim Janssens

Preclinical

2 4

Duragesic-100

CCephalon

Preclinical

2 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 6

Tricor

JJagotec

Preclinical

1 7

Nubain

AAultman Health Foundation

Preclinical

1 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Duragesic

CCephalon

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Renal Cell Carcinoma

NCT03172754

Phase 1Active, not recruiting

Patients With Solid Tumors

NCT04336241

Phase 1Active, not recruiting

Chordoma

NCT02989636

Phase 1Active, not recruiting

Melanoma

NCT03543969

Phase 2Active, not recruiting

Squamous Cell Carcinoma

NCT02919683

Post-ApprovalRecruiting

Infusion

NCT06031233

Clinical

Trials by Indication[1]

Melanoma16 trials

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Completed·IImmodulon Therapeutics Ltd·Phase 2·NCT03711188·16 enrolled

Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Terminated·JJohn Kirkwood·Phase 1/2·NCT04688658·13 enrolled

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT03470922·714 enrolled

Show 13 more trials

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01844505·945 enrolled

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03543969·14 enrolled

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Active, not recruiting·EEmory University·Phase 2·NCT03719131·15 enrolled

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

Terminated·UUniversity of Utah·Phase 2·NCT03259425·7 enrolled

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

Active, not recruiting·MMelanoma Institute Australia·Phase 2·NCT02374242·76 enrolled

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02905266·106 enrolled

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

Recruiting·TThe Netherlands Cancer Institute·Phase 1/2·NCT06240143·96 enrolled

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

Terminated·JJason J. Luke, MD·Phase 1/2·NCT04655157·2 enrolled

A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03980314·261 enrolled

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT03425461·6 enrolled

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

Terminated· Takeda logo

Takeda·Phase 1·NCT02723006·22 enrolled

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03033576·94 enrolled

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT03620019·25 enrolled

Non-Small Cell Lung Cancer12 trials

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Completed·HHeat Biologics·Phase 1/2·NCT02439450·121 enrolled

Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

Withdrawn·SSymphogen A/S·Phase 1/2·NCT02924233

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Terminated·UUniversity of Washington·Phase 1/2·NCT02846792·5 enrolled

Show 9 more trials

Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Active, not recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT04123379·48 enrolled

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

Terminated· Novartis logo

Novartis·Phase 2·NCT02323126·64 enrolled

Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients

Terminated·AAssistance Publique Hopitaux De Marseille·Phase 1·NCT03509584·6 enrolled

A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03195491·400 enrolled

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Recruiting·EEmory University·Phase 2·NCT06495125·50 enrolled

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT05543629·36 enrolled

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· AbbVie logo

AbbVie·Phase 1·NCT02944396·25 enrolled

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT06946797·76 enrolled

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03048136

Lymphoma11 trials

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Active, not recruiting·—·Phase 2·NCT03057795·62 enrolled

Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy

Unknown status·MMeirav Kedmi MD·Phase 2·NCT03569696·50 enrolled

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT03436862·37 enrolled

Show 8 more trials

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04745949·31 enrolled

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Completed· Pfizer logo

Pfizer·Phase 2·NCT01716806·131 enrolled

Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)

Completed·SState Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia·Phase 2·NCT04091490·40 enrolled

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Terminated·MMayo Clinic·Phase 2·NCT03075553·12 enrolled

ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting·UUniversity College, London·Phase 2·NCT03337919·78 enrolled

Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS

Terminated·—·Phase 2·NCT03495713·7 enrolled

Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

Completed·MMayo Clinic·Phase 1·NCT03798314·3 enrolled

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT04134325·10 enrolled

Nivolumab7 trials

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Recruiting·MMayo Clinic·Phase 2·NCT06265285·50 enrolled

Nivolumab+Ipilimumab+RT in MSS mCRC

Unknown status·MMassachusetts General Hospital·Phase 2·NCT04575922·32 enrolled

Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC

Completed·AAVEO Pharmaceuticals, Inc.·Phase 1/2·NCT03136627·28 enrolled

Show 4 more trials

A Study of DF6002 Alone and in Combination With Nivolumab

Completed·DDragonfly Therapeutics·Phase 1·NCT04423029·170 enrolled

Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response

Recruiting·EErasmus Medical Center·Phase 4·NCT06116461·34 enrolled

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT04060407

Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)

Terminated·CCanadian Cancer Trials Group·Phase 2·NCT03461952·4 enrolled

Metastatic Melanoma6 trials

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

Withdrawn·MMayo Clinic·Phase 1·NCT05717140

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma

Terminated·NNewLink Genetics Corporation·Phase 2·NCT03301636·21 enrolled

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02652455·11 enrolled

Show 3 more trials

IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma

Completed·IInstitute of Oncology Ljubljana·N/A·NCT07436390·132 enrolled

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

Completed· Novartis logo

Novartis··NCT05611229·1,975 enrolled

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03635983·783 enrolled

100 more indications

Immunotherapy6 trials

NADIM II: Neo-Adjuvant Immunotherapy

Active, not recruiting·FFundación GECP·Phase 2·NCT03838159·90 enrolled

Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT03808168

DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors

Recruiting·FFundación GECP·Phase 2·NCT05684276·22 enrolled

Show 3 more trials

Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

Not yet recruiting·SSecond Affiliated Hospital of Nanchang University·Phase 2·NCT06554613·156 enrolled

An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03444753·82 enrolled

Brazilian Lung Immunotherapy Study

Completed·HHospital Israelita Albert Einstein·Phase 2·NCT05081674·154 enrolled

Advanced Solid Tumors5 trials

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Active, not recruiting·TTesaro, Inc.·Phase 1·NCT02817633·463 enrolled

A Study of BND-35 in Participants With Advanced Solid Tumors

Recruiting·BBiond Biologics·Phase 1·NCT06274437·280 enrolled

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03184870·332 enrolled

Show 2 more trials

An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03745807·3 enrolled

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT04349267·44 enrolled

Lung Cancer4 trials

Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 3·NCT03469960·265 enrolled

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases

Active, not recruiting·FFundación GECP·Phase 2·NCT05012254·71 enrolled

Repositioning Immunotherapy in VetArans With Lung Cancer

Recruiting·VVA Office of Research and Development·Phase 2·NCT06275360·25 enrolled

Show 1 more trial

Using ctDNA to Determine Therapies for Lung Cancer

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT04966663·66 enrolled

Hepatocellular Carcinoma4 trials

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Terminated·TTransgene·Phase 1/2·NCT03071094·14 enrolled

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Not yet recruiting·FFudan University··NCT07147101·150 enrolled

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT02423343·41 enrolled

Show 1 more trial

P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma

Unknown status·NNational Taiwan University Hospital·Phase 1/2·NCT04233840·72 enrolled

Prostate Cancer4 trials

VAccination in Early and ADvanced Prostate caNCEr

Terminated·UUniversity of Oxford·Phase 1/2·NCT03815942·23 enrolled

Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

Active, not recruiting·—·Phase 2·NCT03637543·31 enrolled

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02985957·351 enrolled

Show 1 more trial

Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)

Unknown status·HHospital Moinhos de Vento·Phase 2·NCT03040791·38 enrolled

Glioblastoma4 trials

Neoadjuvant Nivolumab in Glioblastoma

Completed·—·Phase 2·NCT02550249·29 enrolled

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02311920·32 enrolled

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04817254·47 enrolled

Show 1 more trial

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Terminated·WWashington University School of Medicine·Phase 1·NCT03422094·3 enrolled

Glioma3 trials

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 1·NCT05457959

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

Completed·—·Phase 2·NCT03557359·35 enrolled

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

Recruiting·SSabine Mueller, MD, PhD·Phase 1·NCT04323046·20 enrolled

Esophageal Cancer3 trials

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT06410534

Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06499298·64 enrolled

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03143153·970 enrolled

Solid Tumors3 trials

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Completed· Bayer logo

Bayer·Phase 2·NCT04704154·175 enrolled

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Active, not recruiting·SSarcoma Oncology Research Center, LLC·Phase 1/2·NCT04165330·56 enrolled

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01629758·33 enrolled

Patients With Solid Tumors3 trials

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

Terminated·WWashington University School of Medicine·Phase 1·NCT03511222·16 enrolled

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Active, not recruiting·RReplimune Inc.·Phase 1·NCT04336241·36 enrolled

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Active, not recruiting·BBioAtla, Inc.·Phase 1/2·NCT05180799·320 enrolled

Multiple Myeloma2 trials

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

Withdrawn·—·Phase 2·NCT03227432

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Completed·EEmory University·Phase 1·NCT03605719·23 enrolled

Patients With Advanced Solid Tumors2 trials

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Terminated· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1/2·NCT03311334·47 enrolled

An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03661632·27 enrolled

Bladder Cancer2 trials

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03519256·142 enrolled

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03520491·52 enrolled

Mucosal Melanoma2 trials

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

Active, not recruiting·—·Phase 2·NCT03241186·36 enrolled

Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.

Withdrawn·SSamsung Medical Center·Phase 2·NCT03758729

Treatment2 trials

A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

Completed·OOlivia Newton-John Cancer Research Institute·Phase 2·NCT02923934·120 enrolled

A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC

Completed·—·Phase 2·NCT03380130·41 enrolled

Pancreatic Adenocarcinoma2 trials

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Recruiting·MMayo Clinic·Phase 2·NCT07226856·43 enrolled

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03250273·44 enrolled

Renal Cell Carcinoma2 trials

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Active, not recruiting·FFox Chase Cancer Center·Phase 1/2·NCT03172754·98 enrolled

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02996110·182 enrolled

Breast Cancer2 trials

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Active, not recruiting·—·Phase 2·NCT03789110·30 enrolled

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT04185311·6 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

Terminated·WWashington University School of Medicine·Phase 1/2·NCT03655444·6 enrolled

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169764

Uveal Melanoma2 trials

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03922880·9 enrolled

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Terminated·TTriSalus Life Sciences, Inc.·Phase 1·NCT04935229·67 enrolled

Liver Cancer2 trials

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01658878·657 enrolled

Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer

Terminated·UUniversity of Chicago·Phase 1·NCT03203304·14 enrolled

Chemotherapy2 trials

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03215706·719 enrolled

RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting·AAustralasian Gastro-Intestinal Trials Group·Phase 3·NCT04879368·450 enrolled

Pancreatic Cancer2 trials

Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.

Terminated·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT04212026·8 enrolled

Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.

Completed·HHerlev Hospital·Phase 1/2·NCT04247165·55 enrolled

Soft Tissue Sarcoma2 trials

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Recruiting·SSarcoma Oncology Research Center, LLC·Phase 1/2·NCT03138161·250 enrolled

Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas

Completed·UUniversity Medicine Greifswald·Phase 2·NCT03590210·92 enrolled

Urothelial Carcinoma2 trials

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Active, not recruiting· Roche logo

Roche·Phase 1·NCT05867121·102 enrolled

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Active, not recruiting·EEmory University·Phase 2·NCT04848519·6 enrolled

Squamous Cell Carcinoma2 trials

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

Active, not recruiting·—·Phase 2·NCT02919683·30 enrolled

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02741570·947 enrolled

Chordoma2 trials

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT03623854·10 enrolled

Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02989636·21 enrolled

Metastatic2 trials

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Active, not recruiting·UUniversity of California, San Diego·Phase 2·NCT03646461·5 enrolled

Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation

Withdrawn·UUniversity of Utah·Phase 1·NCT04315155

Combination Therapy2 trials

OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

Completed·GGeorgetown University·Phase 2·NCT03487666·45 enrolled

Regorafenib and Nivolumab Simultaneous Combination Therapy

Completed·KKohei Shitara·Phase 1·NCT03406871·50 enrolled

Neoadjuvant1 trial

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04848116·24 enrolled

Colorectal Cancer1 trial

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Completed·RRedx Pharma Ltd·Phase 2·NCT04907539·25 enrolled

Relapsed/Refractory1 trial

BMS-986012 in Relapsed/Refractory SCLC

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02247349·106 enrolled

Relapse1 trial

HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA

Active, not recruiting·—·Phase 1·NCT02379520·32 enrolled

Ovarian Cancer1 trial

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Terminated·IInge Marie Svane·Phase 1/2·NCT04611126·6 enrolled

Neoadjuvant Immunotherapy1 trial

Neoadjuvant Immunotherapy in Brain Metastases

Terminated·—·Phase 2·NCT04434560·1 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Suspended·NNorthwestern University·Phase 1/2·NCT03704714·30 enrolled

Bone Sarcoma1 trial

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Completed·GGrupo Espanol de Investigacion en Sarcomas·Phase 1/2·NCT03277924·197 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery

Completed·TThe Netherlands Cancer Institute·Phase 2·NCT04620200·50 enrolled

Solid Tumor1 trial

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Active, not recruiting· Eisai logo

Eisai·Phase 1/2·NCT04078295·125 enrolled

Hepatitis B Virus Infection1 trial

Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection

Withdrawn·SShi Ming·Phase 2/3·NCT04044651

Stereotactic Radiation1 trial

Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

Withdrawn·MMedical University of South Carolina·Phase 2·NCT03149159

Small Cell Lung Cancer1 trial

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

Completed·GGeorgetown University·Phase 1/2·NCT03325816·9 enrolled

Basal Cell Carcinoma1 trial

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03521830·57 enrolled

Refractory1 trial

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT03442569·56 enrolled

Pediatric Solid Tumors1 trial

Nivolumab in Relapsed Pediatric Solid Tumors

Unknown status·HHadassah Medical Organization·Phase 1/2·NCT02901145·30 enrolled

Leptomeningeal Metastases1 trial

Ipilimumab and Nivolumab in Leptomeningeal Metastases

Completed·MMassachusetts General Hospital·Phase 2·NCT02939300·18 enrolled

Trial1 trial

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Hematologic Malignancies1 trial

Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies

Terminated·UUniversity of Chicago·Phase 1·NCT02985554·3 enrolled

Metastatic Urothelial Cancer1 trial

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Completed·MMatthew Galsky·Phase 2·NCT03451331·49 enrolled

Renal Cell Cancer1 trial

Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT02989714·13 enrolled

Thyroid Cancer1 trial

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Active, not recruiting·PProvidence Health & Services·Phase 2·NCT04061980·24 enrolled

Endometrial Cancer1 trial

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

Recruiting·YYonsei University·Phase 2·NCT05795244·30 enrolled

Neuroendocrine Tumors1 trial

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT03591731·185 enrolled

TIA1 trial

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study

Completed·UUnknown Sponsor·Phase 2·NCT02631447·251 enrolled

Bevacizumab1 trial

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

Active, not recruiting·DDavid Peereboom·Phase 2·NCT03452579·90 enrolled

Mesothelioma1 trial

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Terminated·—·Phase 2·NCT03502746·34 enrolled

Neoantigen1 trial

A Study of a Personalized Neoantigen Cancer Vaccine

Completed·GGritstone bio, Inc.·Phase 1/2·NCT03639714·29 enrolled

Gastric Cancer1 trial

First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

Recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT06253611·120 enrolled

Head and Neck1 trial

A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck

Active, not recruiting·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 3·NCT03576417·680 enrolled

Esophageal Squamous Cell Cancer1 trial

A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer

Completed·AAIO-Studien-gGmbH·Phase 2·NCT03416244·66 enrolled

Infusion1 trial

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Recruiting·IIsala·Phase 4·NCT06031233·679 enrolled

Recurrent1 trial

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Withdrawn·RReplimune Inc.·Phase 2·NCT05743270

Advanced Head and Neck Cancer1 trial

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Completed·RRTOG Foundation, Inc.·Phase 1·NCT02764593·40 enrolled

Gastroesophageal Junction Cancer1 trial

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02743494·794 enrolled

Metastatic Soft-tissue Sarcoma1 trial

Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study

Active, not recruiting·IInstitut Bergonié·Phase 2·NCT04095208·67 enrolled

Richter Transformation1 trial

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT03121534·9 enrolled

Tics1 trial

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Unknown status·IInfinity Pharmaceuticals, Inc.·Phase 1·NCT02637531·219 enrolled

Tumor Infiltrating Lymphocytes1 trial

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Recruiting·IIovance Biotherapeutics, Inc.·Phase 2·NCT03645928·245 enrolled

Locally Advanced1 trial

APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

Terminated·AApollomics (Australia) Pty. Ltd.·Phase 1/2·NCT03655613·20 enrolled

Adenocarcinoma1 trial

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Withdrawn·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT02466568

Non-Small Cell Lung Carcinoma1 trial

Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma

Terminated·EEric Bernicker, MD·Phase 2·NCT02831933·11 enrolled

Immune Checkpoint Inhibition1 trial

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT03026140·353 enrolled

Refractory Cancer1 trial

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03388632·31 enrolled

Myeloid Leukemia1 trial

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02011945·35 enrolled

Advanced Cancer1 trial

Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02423954·33 enrolled

Esophageal Carcinoma1 trial

A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT04936399·87 enrolled

Pleural Mesothelioma1 trial

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT05136677·102 enrolled

Follicular Lymphoma1 trial

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Completed·—·Phase 1·NCT03892044·7 enrolled

Nasopharyngeal Carcinoma1 trial

Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

Withdrawn·TThe University of Hong Kong·Phase 2·NCT03390738

Azacytidine1 trial

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Recruiting·BBarbara Burtness·Phase 2·NCT05317000·50 enrolled

Advanced NSCLC1 trial

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

Active, not recruiting·HHatim Husain·Phase 1/2·NCT04043195·30 enrolled

Biliary Tract Cancer1 trial

NGS as the First-line Treatment in Advanced Biliary Tract Cancer

Completed·NNational Health Research Institutes, Taiwan·Phase 2·NCT04172402·48 enrolled

Rare Tumor1 trial

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02834013·818 enrolled

Pediatric Patients1 trial

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

Terminated·TThe Hospital for Sick Children·Phase 1/2·NCT02992964·11 enrolled

Safety and Efficacy1 trial

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT04350463·92 enrolled

Malignant Peritoneal Mesothelioma1 trial

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

Completed·UUniversity of Chicago·Phase 2·NCT05041062·2 enrolled

Malignancies1 trial

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Completed·IIncyte Biosciences International Sàrl·Phase 1/2·NCT03126110·145 enrolled

Solid Cancers1 trial

An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02598960·295 enrolled

Advanced Malignancies1 trial

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Terminated· Incyte logo

Incyte·Phase 1/2·NCT02712905·116 enrolled

Malignant Mesothelioma1 trial

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

Active, not recruiting·ÅÅslaug Helland·Phase 2·NCT04300244·118 enrolled

Refractory Tumor1 trial

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Not yet recruiting·MMohammed Milhem·Phase 1·NCT07404332·35 enrolled

Tumors1 trial

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Terminated·TTriSalus Life Sciences, Inc.·Phase 1/2·NCT05220722·23 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03704077

Radiation Therapy1 trial

Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer

Completed·CClaire Verschraegen·Phase 1·NCT03798639·7 enrolled

Advanced or Recurrent Solid Tumors1 trial

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03195478·37 enrolled

Stem Cell Transplant1 trial

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

Withdrawn·SSCRI Development Innovations, LLC·Phase 1·NCT04361058

Uterine Leiomyosarcoma1 trial

Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02428192·20 enrolled

Relapsed/Refractory AML1 trial

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Unknown status·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT03825367·13 enrolled

Kaposi Sarcoma1 trial

Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)

Unknown status·AAlona Zer·Phase 2·NCT03219671·20 enrolled

Gastric Adenocarcinoma1 trial

Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma

Completed·AAIO-Studien-gGmbH·Phase 2·NCT03409848·97 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 22, 2014

Opdivo

BLA 125554

Dec 22, 2014

OPDIVO

BLA BLA125554

Sources

References

[1]
ClinicalTrials.gov — 1505 trial records for Nivolumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Opdivo drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Nivolumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Nivolumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA 125554). U.S. Food & Drug Administration.
[6]
PubMed — 3 publications indexed for Nivolumab. U.S. National Library of Medicine.
[7]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: PD-1 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Bristol-Myers Squibb

Key Publications[6]

Perioperative Nivolumab in Resectable Lung Cancer: CheckMate 816

N Engl J MedNov 17, 2022DOI: 10.1056/NEJMoa2215530

Nivolumab Plus Ipilimumab in Advanced Melanoma: CheckMate 067 Six-Year Results

J Clin OncolJan 13, 2022DOI: 10.1200/JCO.21.02229

Nivolumab in Previously Treated Advanced Hepatocellular Carcinoma

JAMA OncolDec 9, 2021DOI: 10.1001/jamaoncol.2021.5727